NAUT
Nautilus Biotechnology, Inc.
Price Chart
Latest Quote
$2.33
+0.02 (+0.87%)
Current Price
| Previous Close | $2.31 |
| Open | $2.28 |
| Day High | $2.39 |
| Day Low | $2.27 |
| Volume | 306,813 |
Stock Information
| Shares Outstanding | 127.08M |
| Total Debt | $28.87M |
| Cash Equivalents | $95.87M |
| Net Income | $-57.09M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $296.09M |
| EPS (TTM) | $-0.46 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $229.10M |
| Income | $-57.09M |
| Book/sh | $1.14 |
| Cash/sh | $0.75 |
| Employees | 127 |
Financial Ratios
| Quick Ratio | 11.49 |
| Current Ratio | 11.85 |
| Debt/Eq | 19.99 |
Returns & Margins
| ROA | -19.77% |
| ROE | -33.69% |
Ownership
| Insider Ownership | 33.21% |
| Institutional Ownership | 43.53% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -3.15 |
| P/B | 2.05 |
Analyst Data
| Recommendation | none |
| Target Price | $4.00 |
Technical Indicators
| SMA20 | $2.42 |
| SMA50 | $2.62 |
| SMA200 | $2.11 |
| RSI | 32.14 |
| ATR | 0.1536 |
| Shares Float | 52.22M |
| Short Float | 1.22% |
| Short Ratio | 1.90 |
| Volatility | 0.75 |
| Rel Volume | 0.75 |
Performance History
| Week | +3.56% |
| Month | -8.27% |
| Quarter | -35.64% |
| 6 Months | +20.10% |
| YTD | +21.99% |
| Year | +225.87% |
| 3 Years | -41.31% |
| 5 Years | -76.82% |
| 10 Years | -77.68% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $2.33 | 311,800 |
| 2026-06-22 | $2.31 | 446,600 |
| 2026-06-18 | $2.28 | 475,600 |
| 2026-06-17 | $2.18 | 291,000 |
| 2026-06-16 | $2.17 | 393,800 |
| 2026-06-15 | $2.25 | 346,700 |
| 2026-06-12 | $2.24 | 440,100 |
| 2026-06-11 | $2.29 | 548,200 |
| 2026-06-10 | $2.26 | 233,300 |
| 2026-06-09 | $2.35 | 352,200 |
| 2026-06-08 | $2.33 | 441,500 |
| 2026-06-05 | $2.39 | 491,400 |
| 2026-06-04 | $2.68 | 300,400 |
| 2026-06-03 | $2.58 | 368,800 |
| 2026-06-02 | $2.68 | 559,800 |
| 2026-06-01 | $2.77 | 484,400 |
| 2026-05-29 | $2.74 | 542,700 |
| 2026-05-28 | $2.60 | 378,900 |
| 2026-05-27 | $2.56 | 515,800 |
| 2026-05-26 | $2.43 | 384,100 |
About Nautilus Biotechnology, Inc.
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
đ° Latest News
3 Penny Stocks With Market Caps Over $100M To Watch
Simply Wall St. âĸ 2026-06-03T12:05:01Z
3 Promising Penny Stocks With Market Caps Up To $900M
Simply Wall St. âĸ 2026-05-05T12:05:19Z
Nautilus Biotechnology (NASDAQ:NAUT) Is In A Good Position To Deliver On Growth Plans
Simply Wall St. âĸ 2026-05-05T11:05:49Z
Nautilus Biotechnology Inc (NAUT) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...
GuruFocus.com âĸ 2026-04-29T07:05:13ZNautilus Biotechnology Q1 Earnings Call Highlights
MarketBeat âĸ 2026-04-28T15:29:04Z
Here is Why Nautilus Biotechnology (NAUT) is One of the Best Life Sciences Penny Stocks to Buy
Insider Monkey âĸ 2026-04-14T05:59:33Z
Nautilus Biotechnology Unveils Voyager Proteomics Platform, Targets Beta Access in 2H and Launch Next Year
MarketBeat âĸ 2026-03-25T23:08:44Z
Nautilus Biotechnology And 2 Other Compelling Penny Stocks For Your Watchlist
Simply Wall St. âĸ 2026-03-25T12:05:06Z
Nautilus Biotechnology, Inc. Q4 2025 Earnings Call Summary
Moby âĸ 2026-02-27T01:07:08Z
Nautilus Biotechnology Q4 Earnings Call Highlights
MarketBeat âĸ 2026-02-26T22:48:56Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $66,837,000 | $81,476,000 | $76,152,000 | $63,618,000 |
| Other Income Expense | $-32,000 | $-84,000 | $-73,000 | $-122,000 |
| Other Non Operating Income Expenses | $-32,000 | $-84,000 | $-73,000 | $-122,000 |
| Net Non Operating Interest Income Expense | $7,868,000 | $10,780,000 | $12,550,000 | $5,816,000 |
| Operating Expense | $66,837,000 | $81,476,000 | $76,152,000 | $63,618,000 |
| General And Administrative Expense | $25,727,000 | $30,999,000 | $28,901,000 | $25,946,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-59,001,000 | $-70,780,000 | $-63,675,000 | $-57,924,000 |
| Net Interest Income | $7,868,000 | $10,780,000 | $12,550,000 | $5,816,000 |
| Interest Income | $7,868,000 | $10,780,000 | $12,550,000 | $5,816,000 |
| Normalized Income | $-59,001,000 | $-70,780,000 | $-63,675,000 | $-57,924,000 |
| Net Income From Continuing And Discontinued Operation | $-59,001,000 | $-70,780,000 | $-63,675,000 | $-57,924,000 |
| Net Income Common Stockholders | $-59,001,000 | $-70,780,000 | $-63,675,000 | $-57,924,000 |
| Net Income | $-59,001,000 | $-70,780,000 | $-63,675,000 | $-57,924,000 |
| Net Income Including Noncontrolling Interests | $-59,001,000 | $-70,780,000 | $-63,675,000 | $-57,924,000 |
| Net Income Continuous Operations | $-59,001,000 | $-70,780,000 | $-63,675,000 | $-57,924,000 |
| Pretax Income | $-59,001,000 | $-70,780,000 | $-63,675,000 | $-57,924,000 |
| Interest Income Non Operating | $7,868,000 | $10,780,000 | $12,550,000 | $5,816,000 |
| Operating Income | $-66,837,000 | $-81,476,000 | $-76,152,000 | $-63,618,000 |
| Per Share | ||||
| Diluted EPS | $-0.47 | $-0.56 | $-0.51 | $-0.46 |
| Basic EPS | $-0.47 | $-0.56 | $-0.51 | $-0.46 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-60,372,000 | $-75,039,000 | $-70,447,000 | $-60,202,000 |
| Reconciled Depreciation | $6,465,000 | $6,437,000 | $5,705,000 | $3,416,000 |
| EBITDA (Bullshit earnings) | $-60,372,000 | $-75,039,000 | $-70,447,000 | $-60,202,000 |
| EBIT | $-66,837,000 | $-81,476,000 | $-76,152,000 | $-63,618,000 |
| Diluted Average Shares | $126,256,583 | $125,426,509 | $124,919,144 | $124,589,555 |
| Basic Average Shares | $126,256,583 | $125,426,509 | $124,919,144 | $124,589,555 |
| Diluted NI Availto Com Stockholders | $-59,001,000 | $-70,780,000 | $-63,675,000 | $-57,924,000 |
| Research And Development | $41,110,000 | $50,477,000 | $47,251,000 | $37,672,000 |
| Selling General And Administration | $25,727,000 | $30,999,000 | $28,901,000 | $25,946,000 |
| Other Gand A | $25,727,000 | $30,999,000 | $28,901,000 | $25,946,000 |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $156,973,000 | $208,730,000 | $265,353,000 | $314,924,000 |
| Total Assets | $191,112,000 | $242,743,000 | $305,565,000 | $350,052,000 |
| Total Non Current Assets | $85,149,000 | $109,917,000 | $128,728,000 | $162,843,000 |
| Other Non Current Assets | $1,180,000 | $1,180,000 | $1,180,000 | $1,108,000 |
| Current Assets | $105,963,000 | $132,826,000 | $176,837,000 | $187,209,000 |
| Other Current Assets | $2,557,000 | $2,933,000 | $3,419,000 | $2,738,000 |
| Cash Cash Equivalents And Short Term Investments | $103,406,000 | $129,893,000 | $173,418,000 | $184,471,000 |
| Cash And Cash Equivalents | $12,388,000 | $27,646,000 | $19,397,000 | $114,523,000 |
| Non Current Prepaid Assets | - | - | - | $154,000 |
| Non Current Deferred Assets | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $30,019,000 | $30,478,000 | $34,628,000 | $30,328,000 |
| Long Term Debt And Capital Lease Obligation | $26,187,000 | $26,381,000 | $31,090,000 | $28,337,000 |
| Current Debt And Capital Lease Obligation | $3,832,000 | $4,097,000 | $3,538,000 | $1,991,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $34,139,000 | $34,013,000 | $40,212,000 | $35,128,000 |
| Total Non Current Liabilities Net Minority Interest | $26,187,000 | $26,381,000 | $31,090,000 | $28,337,000 |
| Current Liabilities | $7,952,000 | $7,632,000 | $9,122,000 | $6,791,000 |
| Other Current Liabilities | $183,000 | $518,000 | $379,000 | $438,000 |
| Payables And Accrued Expenses | $1,423,000 | $1,674,000 | $2,615,000 | $2,693,000 |
| Payables | $943,000 | $987,000 | $1,639,000 | $1,272,000 |
| Accounts Payable | $943,000 | $987,000 | $1,639,000 | $1,272,000 |
| Equity | ||||
| Common Stock Equity | $156,973,000 | $208,730,000 | $265,353,000 | $314,924,000 |
| Total Equity Gross Minority Interest | $156,973,000 | $208,730,000 | $265,353,000 | $314,924,000 |
| Stockholders Equity | $156,973,000 | $208,730,000 | $265,353,000 | $314,924,000 |
| Gains Losses Not Affecting Retained Earnings | $243,000 | $57,000 | $-255,000 | $-1,854,000 |
| Other Equity Adjustments | $243,000 | $57,000 | $-255,000 | $-1,854,000 |
| Retained Earnings | $-332,020,000 | $-273,019,000 | $-202,239,000 | $-138,564,000 |
| Preferred Securities Outside Stock Equity | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $126,469,610 | $126,106,176 | $125,068,601 | $124,865,485 |
| Share Issued | $126,469,610 | $126,106,176 | $125,068,601 | $124,865,485 |
| Tangible Book Value | $156,973,000 | $208,730,000 | $265,353,000 | $314,924,000 |
| Invested Capital | $156,973,000 | $208,730,000 | $265,353,000 | $314,924,000 |
| Working Capital | $98,011,000 | $125,194,000 | $167,715,000 | $180,418,000 |
| Capital Lease Obligations | $30,019,000 | $30,478,000 | $34,628,000 | $30,328,000 |
| Total Capitalization | $156,973,000 | $208,730,000 | $265,353,000 | $314,924,000 |
| Additional Paid In Capital | $488,737,000 | $481,679,000 | $467,834,000 | $455,330,000 |
| Capital Stock | $13,000 | $13,000 | $13,000 | $12,000 |
| Common Stock | $13,000 | $13,000 | $13,000 | $12,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $26,187,000 | $26,381,000 | $31,090,000 | $28,337,000 |
| Current Capital Lease Obligation | $3,832,000 | $4,097,000 | $3,538,000 | $1,991,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,514,000 | $1,343,000 | $2,590,000 | $1,669,000 |
| Current Accrued Expenses | $480,000 | $687,000 | $976,000 | $1,421,000 |
| Investments And Advances | $52,739,000 | $76,405,000 | $90,647,000 | $129,169,000 |
| Net PPE | $31,230,000 | $32,332,000 | $36,901,000 | $32,566,000 |
| Accumulated Depreciation | $-8,121,000 | $-6,534,000 | $-4,634,000 | $-2,963,000 |
| Gross PPE | $39,351,000 | $38,866,000 | $41,535,000 | $35,529,000 |
| Leases | $118,000 | $118,000 | $118,000 | $13,000 |
| Construction In Progress | $1,807,000 | $1,186,000 | $904,000 | $1,235,000 |
| Other Properties | $8,789,000 | $8,498,000 | $7,333,000 | $5,224,000 |
| Machinery Furniture Equipment | $864,000 | $808,000 | $546,000 | $191,000 |
| Buildings And Improvements | $27,773,000 | $28,256,000 | $32,634,000 | $28,866,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $91,018,000 | $102,247,000 | $154,021,000 | $69,948,000 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-51,973,000 | $-61,267,000 | $-54,153,000 | $-48,130,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-50,696,000 | $-59,145,000 | $-51,711,000 | $-45,806,000 |
| Cash Flow From Continuing Operating Activities | $-50,696,000 | $-59,145,000 | $-51,711,000 | $-45,806,000 |
| Operating Gains Losses | - | $84,000 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-1,277,000 | $-2,122,000 | $-2,442,000 | $-2,324,000 |
| Investing Cash Flow | $35,224,000 | $66,250,000 | $-43,735,000 | $-25,740,000 |
| Cash Flow From Continuing Investing Activities | $35,224,000 | $66,250,000 | $-43,735,000 | $-25,740,000 |
| Net Other Investing Changes | - | $-760,000 | - | - |
| Financing Activities | ||||
| Financing Cash Flow | $214,000 | $1,144,000 | $368,000 | $562,000 |
| Cash Flow From Continuing Financing Activities | $214,000 | $1,144,000 | $368,000 | $562,000 |
| Issuance Of Capital Stock | - | - | - | - |
| Net Other Financing Charges | - | - | - | - |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| End Cash Position | $13,390,000 | $28,648,000 | $20,399,000 | $115,477,000 |
| Beginning Cash Position | $28,648,000 | $20,399,000 | $115,477,000 | $186,461,000 |
| Changes In Cash | $-15,258,000 | $8,249,000 | $-95,078,000 | $-70,984,000 |
| Proceeds From Stock Option Exercised | $214,000 | $1,144,000 | $368,000 | $562,000 |
| Net Investment Purchase And Sale | $36,501,000 | $69,132,000 | $-41,293,000 | $-23,416,000 |
| Sale Of Investment | $108,991,000 | $155,410,000 | $71,599,000 | $163,175,000 |
| Purchase Of Investment | $-72,490,000 | $-86,278,000 | $-112,892,000 | $-186,591,000 |
| Net PPE Purchase And Sale | $-1,277,000 | $-2,122,000 | $-2,442,000 | $-2,324,000 |
| Purchase Of PPE | $-1,277,000 | $-2,122,000 | $-2,442,000 | $-2,324,000 |
| Change In Working Capital | $-3,584,000 | $-5,459,000 | $-3,219,000 | $-788,000 |
| Change In Other Current Liabilities | $-4,688,000 | $-4,150,000 | $-3,208,000 | $-1,392,000 |
| Change In Payables And Accrued Expense | $560,000 | $-1,975,000 | $810,000 | $-152,000 |
| Change In Accrued Expense | $629,000 | $-1,397,000 | $417,000 | $409,000 |
| Change In Payable | $-69,000 | $-578,000 | $393,000 | $-561,000 |
| Change In Account Payable | $-69,000 | $-578,000 | $393,000 | $-561,000 |
| Change In Prepaid Assets | $544,000 | $666,000 | $-821,000 | $756,000 |
| Stock Based Compensation | $6,844,000 | $12,701,000 | $12,137,000 | $10,380,000 |
| Amortization Of Securities | $-1,420,000 | $-2,804,000 | $-2,659,000 | $-890,000 |
| Depreciation Amortization Depletion | $6,465,000 | $6,437,000 | $5,705,000 | $3,416,000 |
| Depreciation And Amortization | $6,465,000 | $6,437,000 | $5,705,000 | $3,416,000 |
| Depreciation | $6,465,000 | $6,437,000 | $5,705,000 | $3,416,000 |
| Net Income From Continuing Operations | $-59,001,000 | $-70,780,000 | $-63,675,000 | $-57,924,000 |
| Other Non Cash Items | - | $760,000 | - | - |
| Gain Loss On Sale Of PPE | - | $84,000 | $0 | $0 |
Fetched: 2026-06-19